Publications
Detailed Information
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dae-Young | - |
dc.contributor.author | Lee, Je-Hwan | - |
dc.contributor.author | Lee, Jung-Hee | - |
dc.contributor.author | Lee, Kyoo-Hyung | - |
dc.contributor.author | Ahn, Jae Sook | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Park, Seonyang | - |
dc.contributor.author | Bang, Soo-Mee | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Oh, Doyeun | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Won, Jong-Ho | - |
dc.contributor.author | Min, Yoo Hong | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Lee, Hong Ghi | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Kim, Hyeoung-Joon | - |
dc.contributor.author | Kim, Yoe-Kyeoung | - |
dc.date.accessioned | 2012-05-29T07:23:59Z | - |
dc.date.available | 2012-05-29T07:23:59Z | - |
dc.date.issued | 2010-01 | - |
dc.identifier.citation | ANNALS OF HEMATOLOGY; Vol.89 1; 15-23 | ko_KR |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76564 | - |
dc.description.abstract | This study was performed to identify whether cytogenetics, International Prognostic Scoring System (IPSS), or World Health Organization Classification-Based Prognostic Scoring System are predictive of the efficacy of azacitidine in patients with myelodysplastic syndrome (MDS). We retrospectively reviewed the clinical records of 113 patients with MDS treated with azacitidine. The "response alternating disease natural history," "cytogenetic response," and "hematologic improvement" were assessed by serial bone marrow biopsy, cytogenetic study, and hemogram analyses. The complete and partial remission rates were 17.6% and 3.9% in 51 evaluable patients. There were no significant differences in response rate in the different cytogenetic/IPSS/WPSS groups. The overall hematologic response (HR) rate was 49.6%, and the HR rate was significantly greater in patients classed as "very high" risk according to the WPSS compared with other patient groups. The 1-year overall survival (OS) rate was higher among patients with HR compared with those without HR (80.9% vs 63.3%, p = 0.046), and the 1-year OS rate among patients classed as being at high risk by each criteria was similar to that of patients classed as being at low risk. The hazard ratio of death among patients with HR compared with those without HR was 0.17 (95% CI 0.04-0.69) for high + very high risk group based on WPSS. Patients in the WPSS high-risk group had an increased HR rate compared with other patient groups, and the achievement of HR was associated with a significant increase in OS. Azacitidine showed similar efficacy in all patient groups, even in patients with poor cytogenetics and in high-risk groups. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPRINGER | ko_KR |
dc.subject | Azacitidine | ko_KR |
dc.subject | Cytogenetics | ko_KR |
dc.subject | WPSS | ko_KR |
dc.subject | IPSS | ko_KR |
dc.title | Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김대영 | - |
dc.contributor.AlternativeAuthor | 이제환 | - |
dc.contributor.AlternativeAuthor | 이정희 | - |
dc.contributor.AlternativeAuthor | 이규형 | - |
dc.contributor.AlternativeAuthor | 김요경 | - |
dc.contributor.AlternativeAuthor | 안재숙 | - |
dc.contributor.AlternativeAuthor | 김형준 | - |
dc.contributor.AlternativeAuthor | 김인호 | - |
dc.contributor.AlternativeAuthor | 윤성수 | - |
dc.contributor.AlternativeAuthor | 박선양 | - |
dc.contributor.AlternativeAuthor | 배성화 | - |
dc.contributor.AlternativeAuthor | 방수미 | - |
dc.contributor.AlternativeAuthor | 이홍기 | - |
dc.contributor.AlternativeAuthor | 신호진 | - |
dc.contributor.AlternativeAuthor | 이재훈 | - |
dc.contributor.AlternativeAuthor | 민유홍 | - |
dc.contributor.AlternativeAuthor | 원종호 | - |
dc.contributor.AlternativeAuthor | 오도연 | - |
dc.contributor.AlternativeAuthor | 문영철 | - |
dc.identifier.doi | 10.1007/s00277-009-0771-1 | - |
dc.citation.journaltitle | ANNALS OF HEMATOLOGY | - |
dc.description.citedreference | Oki Y, 2007, INT J HEMATOL, V86, P306, DOI 10.1532/IJH97.07034 | - |
dc.description.citedreference | Raj K, 2007, LEUKEMIA, V21, P1937, DOI 10.1038/sj.leu.2404796 | - |
dc.description.citedreference | Malcovati L, 2007, J CLIN ONCOL, V25, P3503, DOI 10.1200/JCO.2006.08.5696 | - |
dc.description.citedreference | Kantarjian HM, 2007, CANCER, V109, P1133, DOI 10.1002/cncr.22508 | - |
dc.description.citedreference | Plimack ER, 2007, LEUKEMIA LYMPHOMA, V48, P1472, DOI 10.1080/10428190701471981 | - |
dc.description.citedreference | Silverman LR, 2006, J CLIN ONCOL, V24, P3895, DOI 10.1200/JCO.2005.05.4346 | - |
dc.description.citedreference | Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149 | - |
dc.description.citedreference | Wijermans PW, 2005, ANN HEMATOL, V84, P9, DOI 10.1007/s00277-005-0012-1 | - |
dc.description.citedreference | van den Bosch J, 2004, LEUKEMIA RES, V28, P785 | - |
dc.description.citedreference | Leone G, 2003, CLIN IMMUNOL, V109, P89, DOI 10.1016/S1521-6616(03)00207-9 | - |
dc.description.citedreference | Lubbert M, 2003, LEUKEMIA, V17, P1762, DOI 10.1038/sj.leu.2403045 | - |
dc.description.citedreference | Daskalakis M, 2002, BLOOD, V100, P2957 | - |
dc.description.citedreference | Gryn J, 2002, LEUKEMIA RES, V26, P893 | - |
dc.description.citedreference | Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117 | - |
dc.description.citedreference | Lubbert M, 2001, BRIT J HAEMATOL, V114, P349 | - |
dc.description.citedreference | Greenberg P, 1997, BLOOD, V89, P2079 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.